Stock Events

Stock Events

Leap Therapeutics 

0
120
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q1 2026
Q2 2026
Next
-0.39
-0.21
-0.03
0.16
Expected EPS
0.008602
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
3.06MNet Income

Analyst Ratings

1.21Average Price Target
The highest estimate is 1.21.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5MC1.STU. It's not an investment recommendation.
Apple
7
AAPL
Microsoft
7
MSFT
Amazon
7
AMZN
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Leap Therapeutics' focus on cancer immunotherapies.
Merck
MRK
Mkt Cap366B
Merck is a leading competitor in the oncology market, particularly with its blockbuster cancer drug Keytruda, which competes directly with cancer therapies developed by Leap Therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, competes in the cancer treatment space, including immunotherapies that directly compete with Leap Therapeutics' pipeline.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong presence in the oncology sector, including immunotherapy treatments that rival Leap Therapeutics' cancer therapy developments.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse oncology portfolio that includes immunotherapies and targeted cancer treatments, competing with Leap Therapeutics' focus areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its Kite Pharma acquisition, competes in the cancer immunotherapy space, directly challenging Leap Therapeutics' therapeutic approaches.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a growing oncology and hematology portfolio that includes treatments which could compete with Leap Therapeutics' cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing a range of cancer treatments, including immunotherapies that could compete with Leap Therapeutics' products.
Novartis
NVS
Mkt Cap292.35B
Novartis has a strong focus on oncology, with a portfolio that includes cancer immunotherapies and targeted treatments that rival Leap Therapeutics' developments.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen subsidiary, develops a variety of oncology treatments, including immunotherapies that could compete with Leap Therapeutics' pipeline.

About

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Show more...
CEO
Douglas E. Onsi
Employees
6
Country
United States
ISIN
US52187K1016
WKN
000A3EMJP

Listings

STU
DE
5MC.STU
MU
DE
5MC1.MU
STU
DE
5MC1.STU
MU
DE
5MC.MU

0 Comments

Share your thoughts

FAQ

What is Leap Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Leap Therapeutics stocks are traded under the ticker 5MC1.STU.
When is the next Leap Therapeutics earnings date?▼
Leap Therapeutics is going to release the next earnings report on November 16, 2026.
What were Leap Therapeutics earnings last quarter?▼
5MC1.STU earnings for the last quarter are 0.16 EUR per share, whereas the estimation was -0.03 EUR resulting in a +700% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Leap Therapeutics revenue for the last year?▼
Leap Therapeutics revenue for the last year amounts to 0 EUR.
What is Leap Therapeutics net income for the last year?▼
5MC1.STU net income for the last year is 3.06M EUR.
How many employees does Leap Therapeutics have?▼
As of September 04, 2026, the company has 6 employees.
In which sector is Leap Therapeutics located?▼
Leap Therapeutics operates in the Finance & Payments sector.
When did Leap Therapeutics complete a stock split?▼
The last stock split for Leap Therapeutics was on June 21, 2023 with a ratio of 1:10.
Where is Leap Therapeutics headquartered?▼
Leap Therapeutics is headquartered in CAMBRIDGE, United States.